Autistic Disorder

2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

BioMarin Pharmaceutical
2 programs
1
1
Kuvan®Phase 2/31 trial
sapropterinPhase 21 trial
Active Trials
NCT00850070Completed46Est. Oct 2011
NCT00943579Completed41Est. Mar 2012
Function Therapeutics
Function TherapeuticsWI - Milwaukee
1 program
Autistic functional explorationN/A1 trial
Active Trials
NCT01984944CompletedEst. Aug 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BioMarin PharmaceuticalKuvan®
BioMarin Pharmaceuticalsapropterin
Function TherapeuticsAutistic functional exploration

Clinical Trials (3)

Total enrollment: 87 patients across 3 trials

NCT00943579BioMarin PharmaceuticalKuvan®

Open-Label Extension Study of Kuvan for Autism

Start: Aug 2009Est. completion: Mar 201241 patients
Phase 2/3Completed
NCT00850070BioMarin Pharmaceuticalsapropterin

Sapropterin as a Treatment for Autistic Disorder

Start: Mar 2009Est. completion: Oct 201146 patients
Phase 2Completed
NCT01984944Function TherapeuticsAutistic functional exploration

Characterisation of Circadian Rhythm in Autistic Spectrum Disorder

Start: Oct 2009Est. completion: Aug 2013
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space